Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CEFOTAXIME
Sandoz GmbH
2 Grams
Solution for Inj/Inf
2002-12-06
License Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Cefotaxime 2 g Powder for Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 g vial contains 2 g cefotaxime (as cefotaxime sodium). Sodium content: 96 mg/vial. 3 PHARMACEUTICAL FORM Powder for solution for injection or infusion. Description: Sterile, crystalline, white to slightly yellow powder for solution for injection or infusion. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Cefotaxime is indicated for the treatment of the following severe infections when known or thought very likely to be due to bacteria that are susceptible to cefotaxime (see section 5.1, Pharmacodynamic properties): o Bacterial pneumonia; cefotaxime is not active against bacteria that cause atypical pneumonia or against several other bacterial species that may cause pneumonia, including P. aeruginosa (see section 5.1, Pharmacodynamic properties). o Complicated infections of the kidneys and upper urinary tract. o Severe infections of the skin and soft tissue. o Genital infections caused by gonococci, particularly when penicillin has failed or is unsuitable. o Intra-abdominal infections (Such as peritonitis). Cefotaxime should be used in combination with an antibiotic that is Read the complete document